US Patent

US9012462 — Phosphorous derivatives as kinase inhibitors

Composition of Matter · Assigned to Ariad Pharmaceuticals Inc · Expires 2031-04-28 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects phosphorous derivatives that act as kinase inhibitors.

USPTO Abstract

The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.

Drugs covered by this patent

Patent Metadata

Patent number
US9012462
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-04-28
Drug substance claim
Yes
Drug product claim
No
Assignee
Ariad Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.